{
  "paper_id": "PMC9780106",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780106/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Fig. 1. Pooled seroconversion rates following complete primary SARS-CoV-2 vaccination in patients with hematologic malignancies compared to those of healthy controls and patients with solid cancers.",
      "caption": "Pooled seroconversion rates of hematologic malignancy patients with treatment and those without treatment were calculated from studies with disaggregated data on treatment.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/1a70b17d159b/41408_2022_776_Fig1_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/1a70b17d159b/41408_2022_776_Fig1_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/1a70b17d159b/41408_2022_776_Fig1_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/1a70b17d159b/41408_2022_776_Fig1_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/1a70b17d159b/41408_2022_776_Fig1_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9780106/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/1a70b17d159b/41408_2022_776_Fig1_HTML.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Fig. 2. Pooled seroconversion rates following complete primary SARS-CoV-2 vaccination in each disease subtype of hematologic malignancies.",
      "caption": "CLL chronic lymphocytic leukemia, HL Hodgkin lymphoma, Leukemia acute leukemia, MDS myelodysplastic syndrome, MM multiple myeloma, MPN myeloproliferative neoplasms, NHL non-Hodgkin lymphoma.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/4a14559070d4/41408_2022_776_Fig2_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/4a14559070d4/41408_2022_776_Fig2_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/4a14559070d4/41408_2022_776_Fig2_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/4a14559070d4/41408_2022_776_Fig2_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/4a14559070d4/41408_2022_776_Fig2_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9780106/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/4a14559070d4/41408_2022_776_Fig2_HTML.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Fig. 3. The pooled seroconversion rate following SARS-CoV-2 booster vaccination in patients with hematologic malignancies.",
      "caption": "The pooled analysis of 21 studies containing 1518 patients with hematologic malignancies showed that the pooled seroconversion rate after booster vaccination was 40.5% (95% confidence interval [CI], 33.0–48.4%).",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/594fcdd7a1fc/41408_2022_776_Fig3_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/594fcdd7a1fc/41408_2022_776_Fig3_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/594fcdd7a1fc/41408_2022_776_Fig3_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/594fcdd7a1fc/41408_2022_776_Fig3_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/594fcdd7a1fc/41408_2022_776_Fig3_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9780106/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/594fcdd7a1fc/41408_2022_776_Fig3_HTML.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Fig. 4. The pooled proportion of neutralizing antibody development following primary SARS-CoV-2 vaccination in patients with hematologic malignancies.",
      "caption": "The pooled analysis of 21 studies containing 2011 patients with hematologic malignancies showed that the pooled proportion of neutralizing antibody development was 52.8% (95% confident interval [CI], 45.8–59.7%).",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/4273924fcd7e/41408_2022_776_Fig4_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/4273924fcd7e/41408_2022_776_Fig4_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/4273924fcd7e/41408_2022_776_Fig4_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/4273924fcd7e/41408_2022_776_Fig4_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/4273924fcd7e/41408_2022_776_Fig4_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9780106/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/4273924fcd7e/41408_2022_776_Fig4_HTML.jpg"
    },
    "figure_5": {
      "figure_number": "Figure 5",
      "title": "Fig. 5. The pooled proportion of the specific SARS-CoV-2 T-cell response following primary SARS-CoV-2 vaccination in patients with hematologic malignancies.",
      "caption": "The pooled analysis of 17 studies containing 872 patients with hematologic malignancies showed that the pooled proportion of cellular immune responses was 66.6% (95% confidence interval [CI], 57.1–74.9%).",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/964fbf91d2d1/41408_2022_776_Fig5_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/964fbf91d2d1/41408_2022_776_Fig5_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/964fbf91d2d1/41408_2022_776_Fig5_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/964fbf91d2d1/41408_2022_776_Fig5_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig5",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/964fbf91d2d1/41408_2022_776_Fig5_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9780106/images/figure_5.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7035/9780237/964fbf91d2d1/41408_2022_776_Fig5_HTML.jpg"
    }
  },
  "claims": [
    {
      "sentence": "The pooled seroconversion rate after booster vaccination was 40.5% (95% CI, 33.0–48.4%; I2 = 87%) (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The pooled seroconversion rate after booster vaccination was 40.5% (95% CI, 33.0–48.4%; I2 = 87%) (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The pooled proportion of neutralizing antibody development was 52.8% (95% CI; 45.8–59.7%, I2 = 87%) (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The pooled proportion of neutralizing antibody development was 52.8% (95% CI; 45.8–59.7%, I2 = 87%) (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The pooled proportion of cellular immune responses was 66.6% (95% CI, 57.1–74.9%; I2 = 86%) (Fig. 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The pooled proportion of cellular immune responses was 66.6% (95% CI, 57.1–74.9%; I2 = 86%) (Fig. 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 5,
    "claims_count": 6,
    "images_downloaded": 5,
    "tables_filtered": 47
  }
}